4.7 Review

Antithrombotic P2Y12 receptor antagonists: recent developments in drug-discovery

Journal

DRUG DISCOVERY TODAY
Volume 24, Issue 1, Pages 325-333

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.09.021

Keywords

-

Funding

  1. Sultan Qaboos University (SQU) [SR/SCI/CHEM/15/01]
  2. Arab-German Young Academy of Sciences and Humanities (AGYA) [TP_2017_27, TP_2018_08]

Ask authors/readers for more resources

The P2Y(12) receptor is one of eight known P2Y receptor subtypes, and belongs to the G-protein-coupled receptor (GPCR) family. The P2Y(12) receptor is highly expressed on blood platelets and in the brain. Potent, selective, peripherally acting antagonists for the P2Y(12) receptor are used clinically as antithrombotic drugs. Several different scaffolds have been identified as P2Y(12) receptor antagonists, including irreversibly acting thienotetrahydropyridines (prodrugs), and reversible competitive antagonists, including adenine nucleotide analogs, piperazinyl-glutamate-quinolines, -pyridines, and -pyrimidines, and anthraquinone derivatives. Here, we provide an overview of the different scaffolds that have been developed as P2Y(12) receptor antagonists, some of which have become important therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available